AI in Australian Healthcare: Diagnostics, Patient Flow, Drug Discovery and Clinical Governance product guide

AI in Australian Healthcare: Diagnostics, Patient Flow, Drug Discovery and Clinical Governance

Australia's healthcare system is under genuine pressure. A rapidly ageing population, chronic disease burden, geographic inequity, and a persistent workforce shortage are all converging at the exact moment AI has matured from experimental curiosity to operational tool.

The numbers make this concrete. By 2066, around 21% of Australia's population will be over 65, while chronic diseases already account for 90% of deaths in the country. AI isn't a luxury add-on in this context — it's becoming load-bearing infrastructure.

Australia's AI healthcare market hit approximately AU$197.6 million in 2023 and is projected to reach AU$2.16 billion by 2030, with generative AI alone potentially adding AU$13 billion annually to the sector by 2030. But this isn't purely a growth story. It's a story about governance, safety, and the hard work of translating algorithms into clinical reality.

This article covers four domains where Australian healthcare AI is making measurable impact right now: medical imaging diagnostics, patient flow and admission forecasting, drug discovery, and clinical governance. It also maps the regulatory obligations every health technology operator in Australia needs to understand before a single model goes near a patient.

AI-powered diagnostics: from radiology to pathology

Medical imaging: the highest-velocity use case

Medical imaging is the most mature AI application in Australian healthcare, and the momentum is real. Machine learning algorithms can examine MRIs, CT scans, and X-rays to identify anomalies with considerable accuracy, often catching early signs of cancer, fractures, or cardiac problems that human eyes might miss.

At the Royal Melbourne Hospital, AI-powered diagnostic tools are helping radiologists detect early-stage cancers, reducing diagnostic errors and improving patient outcomes. This isn't a pilot sitting in a lab — it's embedded in clinical operations. A joint University of Melbourne and Royal Melbourne Hospital initiative led by Professor Peter Steel is working to accelerate healthcare transformation through digital innovation, a role described as unique in Australia, reflecting both institutions' shared commitment to embedding AI and data science directly into clinical practice and research.

South Australia has deployed Annalise.ai tools across metropolitan and regional sites to assist with chest X-ray diagnoses — a deployment that directly addresses the equity problem of rural Australians receiving lower-quality diagnostic reads because of radiologist shortages. That's AI doing practical work in the real world.

In breast cancer detection, the impact is significant. A study published in the Journal of Medical Imaging and Radiation Oncology found that AI is substantially helping health professionals improve accurate breast cancer diagnoses and elevating patient outcomes.

The My Health Record advantage — and its constraints

Australia has a structural head start here. The nationwide adoption of My Health Record — a digital repository containing over 23 million Australians' health data — gives AI systems a critical foundation for developing more accurate predictive models, optimising care delivery, and identifying early warning signs of diseases like cancer.

But that asset comes with real constraints. Despite the volume of healthcare data available through government systems, decentralisation and fragmentation make it difficult to incorporate into AI applications. Inconsistent data formats across hospitals, clinics, and health systems slow AI-driven analysis and, by extension, adoption.

The CSIRO's AI Trends for Healthcare report (March 2024) captures this dynamic well. It notes that the digitalisation of Australia's hospital records through electronic medical records is rapidly expanding, and that EMRs and other clinical systems are likely to provide the platform for implementing AI technologies — covering imaging, diagnosis, treatment, report reconciliation, and clinical data analysis.

The foundation is solid. The integration work is where the real effort lies.

Patient flow and admission forecasting

Predictive analytics in hospital operations

One of the most operationally impactful AI applications in Australian hospitals right now is patient flow prediction — using historical admission data, seasonal patterns, and real-time inputs to forecast demand on emergency departments, surgical wards, and ICUs.

St. Vincent's Health Australia, one of the country's largest healthcare providers, has brought in AI-driven solutions to improve patient flow across its hospitals. Through predictive analytics, the network can forecast patient admissions, reduce wait times, and allocate resources more effectively.

Monash Health, Victoria's largest public health service, is using AI to improve early detection of patient deterioration and support clinical decision-making. By deploying AI algorithms, Monash Health can identify high-risk patients and intervene earlier, reducing emergency admissions. Real-time patient monitoring systems provide continuous oversight to ensure timely interventions.

The Queensland Government is also using AI to predict hospital demand with the aim of cutting patient waiting times across the state.

Why patient flow AI matters for Australia's hospital funding crisis

This connects directly to Australia's healthcare funding reality. The federal government has committed AU$7.9 billion to strengthen public hospitals and health services, targeting ambulance ramping, emergency department delays, and surgical backlogs. AI-driven patient flow optimisation is one of the few scalable tools that can genuinely amplify the impact of that investment — reducing cost per intervention by improving the timing and placement of clinical resources.

The Productivity Commission estimated that adopting smart health services could save over AU$5 billion a year and ease pressure on Australia's healthcare system. That's system-level impact, not a marginal efficiency gain.

AI in drug discovery: Australia's research frontier

Compressing the drug development timeline

Traditional pharmaceutical development is slow and expensive. Taking one drug candidate from initial discovery through to market approval typically takes 10–15 years and costs over AU$1 billion. AI is starting to compress that timeline by automating target identification, molecular screening, and clinical trial design.

Research findings show that AI lowers costs, shortens development timelines, and improves predictive capability, with applications in molecular modelling, drug design and screening, and clinical trial design.

Australia's CSIRO is directly involved. A cross-disciplinary team — supported by the Minimising Antimicrobial Resistance Mission, the Infectious Disease Resilience Mission, and the AI4Missions initiative — is developing AI tools to accelerate drug discovery and reduce costs in the lead-up to clinical trials.

CSIRO's HCA-Vision platform, which uses AI-powered high-content analysis, is used by biomedical research institutes and pharmaceutical companies in Australia and overseas, helping researchers identify more effective, safer pharmaceuticals and better understand disease mechanisms.

The global context: where Australian pharma fits

The global picture is striking. AI is reducing drug development timelines from 12–15 years to as little as 18–30 months whilst cutting costs by 50–80% in preclinical stages. As of 2025, over 31 AI-discovered drugs are in clinical trials, with the market expected to reach US$16.5 billion by 2034.

For Australian pharmaceutical operators, this creates both opportunity and obligation. Research institutions partnering with global AI-drug platforms must navigate TGA requirements for any resulting therapeutic goods — a consideration that shapes how Australian clinical trial data is collected, structured, and used for model training. Get this right from the start and you're positioned to move fast. Get it wrong and you're rebuilding from scratch.

Clinical governance: what responsible AI deployment actually requires

The TGA regulatory framework for AI medical devices

Australia's Therapeutic Goods Administration (TGA) is the primary regulatory gatekeeper for AI tools deployed in clinical settings. The framework is more demanding than many developers initially expect.

Software and AI are classified as medical devices if they help diagnose, monitor, or treat health conditions. Unless exempt or excluded, all medical devices must be listed on the Australian Register of Therapeutic Goods (ARTG) to be legally supplied in Australia.

The TGA's 2025 compliance update focuses heavily on AI and software-based medical devices. Under the Therapeutic Goods Act 1989, some advanced AI tools — including digital scribes that suggest diagnoses or treatments — may be regulated as medical devices. Developers and suppliers must ensure compliance, including ARTG registration where required.

One point that catches international operators off guard: if an AI medical device is supplied to people in Australia, it falls under the medical device regulations regardless of where the developer is based. That's a direct regulatory obligation for any international AI health platform operating in the Australian market without local regulatory approval.

AI developers must also understand and demonstrate the sources and quality of text inputs used to train and test the model, and in clinical studies, must show how the data is generalisable and appropriate for use on Australian populations.

The TGA's post-consultation position (2025)

In late 2024, the TGA ran a consultation on clarifying and strengthening the regulation of medical device software including AI, asking directly whether existing legislation, regulations, and guidance are fit for purpose.

The outcome was measured rather than sweeping. The report found that the current regulatory framework is largely adequate to deal with AI, but noted that some adjustments to definitions and offence provisions may be needed to clarify the role of entities in the AI lifecycle. In January 2025, the Government approved undertaking further work in response to the 14 key findings of the report.

Medical device manufacturers and developers of health-related AI can expect further practical guidance on technical requirements for adaptive and generative AI, and standards for using and validating datasets of unknown provenance.

Evidence requirements for AI medical devices

The TGA's evidence framework for AI medical devices is detailed and lifecycle-oriented. Manufacturers of software medical devices that include AI must have evidence of how the device complies with the Essential Principles. This evidence must be sufficiently transparent to enable evaluation of safety and performance, and must include what the AI/ML model is doing and how it contributes to the intended purpose of the device, plus a description of the algorithm and model design, including information on the training and testing phases.

Risk management evidence must address AI-specific risks including overfitting, bias, and performance degradation such as data drift. And it doesn't stop at launch — evidence requirements continue through the product lifecycle and include post-market monitoring practices to ensure continued device performance and model accuracy.

AHPRA and clinical professional obligations

TGA compliance is necessary but not the whole picture. Health practitioners using AI medical devices in clinical practice should be mindful of the AHPRA guidance on meeting professional obligations when using artificial intelligence in healthcare. That creates a dual-layer obligation: the device must be TGA-compliant, and the clinician using it must exercise independent professional judgement.

This is particularly relevant for AI clinical decision support systems. Research published in JAMIA (2025) by authors from the Centre for Digital Transformation of Health at the University of Melbourne and the Royal Melbourne Hospital found something that should give every healthcare AI developer pause: despite the surge in development of AI algorithms to support clinical decision-making, few of these algorithms are used in practice. The study assessed the maturity of AI-CDSS implementation research and found significant gaps between development and real-world deployment.

The technical infrastructure required to deploy AI-CDSS has been minimally explored compared to the efforts to develop AI models — a significant challenge for hospitals and health services considering adoption.

Building a great model is step one. Getting it into clinical practice is the hard part.

Adoption barriers and uneven uptake

The opportunity is clear. The adoption reality is more complicated. AI applications in healthcare include diagnosis (42%) and treatment planning (46%), yet adoption is uneven: only 51% of small health businesses are using AI, and 32% of SMEs have no plans to adopt AI because of privacy and ethics concerns.

Data security is a live issue. In 2022, Australia's Office of the Australian Information Commissioner reported that health service providers were among the top five sectors to notify data breaches, raising concerns about AI's role in handling personal medical information.

The workforce challenge is equally real. As Professor Enrico Coiera, Director of the Centre for Health Informatics at the Australian Institute of Health Innovation, Macquarie University, puts it: for Australia's health system to benefit from the AI-powered healthcare revolution, it needs more than new technology. It needs the research evidence, skills, and workforce to translate these advances into effective working health services.

The skills dimension is a current constraint, not a future one. For a detailed analysis of the AI workforce gap and upskilling pathways, see our guide on AI Skills Gap in Australia: Workforce Readiness, Training Programs and the Talent Shortage by Industry.

TGA AI medical device compliance: a decision framework

Before any AI tool goes near a clinical setting in Australia, every health technology operator needs to work through these questions.

For a comprehensive treatment of data residency and consent obligations, see our guide on AI Data Sovereignty and Privacy Compliance for Australian Organisations.

Key takeaways

• Australia's AI healthcare market is projected to grow from AUD 80 million in 2022 to AUD 1.78 billion by 2030, at a compound annual growth rate of 46.72% — one of the fastest-growing AI verticals in the country. The window to build and deploy is now.

• Medical imaging AI is the most mature deployment domain, with hospitals including the Royal Melbourne Hospital and South Australian health networks already using tools like Annalise.ai for diagnostic support — but governance structures must accompany every deployment.

• Australia's TGA has released a 2025 compliance update clarifying how AI and software-based tools, such as digital scribes with diagnostic or treatment functions, may fall under medical device regulations — a direct regulatory obligation for any operator deploying AI in a clinical context. Know this before you build, not after.

• CSIRO's AI4Missions program is actively developing AI tools to accelerate drug discovery and reduce costs in the lead-up to clinical trials, positioning Australia as a contributor — not just a consumer — of pharmaceutical AI innovation.

• The gap between AI model development and real-world clinical deployment remains the defining challenge: despite the surge in development of AI algorithms to support clinical decision-making, few of these algorithms are used in practice — a finding that should anchor every healthcare AI implementation strategy from day one.

Conclusion

AI in Australian healthcare is well past the proof-of-concept stage. Diagnostics, patient flow management, drug discovery, and clinical decision support are all seeing real-world deployments at major institutions including the Royal Melbourne Hospital, Monash Health, St. Vincent's Health Australia, and within CSIRO's research programs. The regulatory environment, anchored by the TGA's evolving AI medical device framework, is broadly adequate but actively developing, with further guidance on adaptive and generative AI models on the way.

What separates successful deployments from expensive experiments is governance: evidence-based validation, ARTG compliance, AHPRA-aligned clinical oversight, and a clear position on data sovereignty under Australia's Privacy Act 1988. The market opportunity is real — and so is the accountability that comes with it.

For healthcare organisations beginning their AI journey, the next step is building the internal readiness that makes deployment sustainable. See our guide on How to Build an AI Strategy for an Australian Business for a step-by-step implementation framework. For those assessing risk before committing, see AI Risks and Ethical Challenges Facing Australian Industries, which examines algorithmic bias in healthcare decisions and liability gaps in clinical AI systems. And for the broader regulatory context that frames every sector-specific obligation discussed here, see Australia's AI Regulatory Framework: Ethics Principles, Governance Standards and What Businesses Must Know.

The healthcare sector's AI transformation isn't a future event. It is already underway — and the institutions that govern it well will define what high-quality, equitable Australian healthcare looks like in 2030.

References

• Australian Institute of Health and Welfare (AIHW). Australia's Health 2024. AIHW, 2024. https://www.aihw.gov.au/reports-data/australias-health

• CSIRO Australian e-Health Research Centre. AI Trends for Healthcare. CSIRO, March 2024. https://aehrc.csiro.au/wp-content/uploads/2024/03/AI-Trends-for-Healthcare.pdf

• Therapeutic Goods Administration (TGA). Artificial Intelligence (AI) and Medical Device Software. Australian Government Department of Health, Disability and Ageing, 2025. https://www.tga.gov.au/products/medical-devices/software-and-artificial-intelligence/manufacturing/artificial-intelligence-ai-and-medical-device-software

• Therapeutic Goods Administration (TGA). Evidence Requirements for Software Using AI. Australian Government, 2025. https://www.tga.gov.au/products/medical-devices/software-and-artificial-intelligence/manufacturing/artificial-intelligence-ai-and-medical-device-software/evidence-requirements-software-using-ai

• Therapeutic Goods Administration (TGA). Consultation: Clarifying and Strengthening the Regulation of Artificial Intelligence (AI). Australian Government, 2025. https://www.tga.gov.au/resources/consultation/consultation-clarifying-and-strengthening-regulation-artificial-intelligence-ai

• CSIRO AI for Missions Program. AI for Drug Discovery: Our Focus on Emerging Infectious Diseases. CSIRO Research, 2023. https://research.csiro.au/ai4m/ai-for-drug-discovery-our-focus-on-emerging-infectious-diseases/

• Coiera, Enrico. Decoding the Revolution of AI-Powered Healthcare. National Health and Medical Research Council (NHMRC), 2024. https://www.nhmrc.gov.au/about-us/news-centre/decoding-revolution-ai-powered-healthcare

• University of Melbourne Faculty of Medicine, Dentistry and Health Sciences. New Role Harnesses Digital Health Innovation and AI at University of Melbourne and the Royal Melbourne Hospital. University of Melbourne, 2025. https://mdhs.unimelb.edu.au/news-and-events/new-role-harnesses-digital-health-innovation-and-ai-at-university-of-melbourne-and-the-royal-melbourne-hospital

• Vandenberg, M. et al. "Bridging the Gap: Challenges and Strategies for the Implementation of Artificial Intelligence-based Clinical Decision Support Systems in Clinical Practice." JAMIA, 2025. https://pubmed.ncbi.nlm.nih.gov/40199296/ (Authors affiliated with Centre for Digital Transformation of Health, University of Melbourne & Royal Melbourne Hospital)

• Maraqa, B. et al. "AI-Driven Clinical Decision Support Systems: An Ongoing Pursuit of Potential." PMC/PubMed Central, 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11073764/

• Office of the Australian Information Commissioner (OAIC). Notifiable Data Breaches Report. OAIC, 2022. https://www.oaic.gov.au/privacy/notifiable-data-breaches

• Qualtech. AI Transformation in Australian Healthcare: Market Growth and Regulatory Insights 2025. Qualtech, 2025. https://www.qualtechs.com/en-gb/article/ai-healthcare-australia-2025-overview

Frequently Asked Questions

What is Australia's AI healthcare market revenue in 2023: Approximately AU$197.6 million

What is Australia's AI healthcare market projected to reach by 2030: AU$2.16 billion

What could generative AI add annually to Australia's healthcare sector by 2030: AU$13 billion

What percentage of Australia's population will be over 65 by 2066: Approximately 21%

What percentage of deaths in Australia are caused by chronic diseases: 90%

What is the most mature AI application in Australian healthcare: Medical imaging diagnostics

Which hospital uses AI-powered tools to detect early-stage cancers: Royal Melbourne Hospital

Which AI tool has been deployed across South Australian health sites for chest X-rays: Annalise.ai

How many Australians have data stored in My Health Record: Over 23 million

Does My Health Record provide a foundation for AI diagnostics: Yes

Does data fragmentation hinder AI adoption in Australian healthcare: Yes

What causes data fragmentation in Australian healthcare AI: Inconsistent data formats across hospitals and clinics

Which institution published the CSIRO AI Trends for Healthcare report: CSIRO, March 2024

What does the CSIRO AI Trends for Healthcare report identify as the platform for AI implementation: Electronic medical records (EMRs)

Which healthcare network uses AI-driven solutions to improve patient flow: St. Vincent's Health Australia

Which Victorian health service uses AI for early detection of patient deterioration: Monash Health

Is Monash Health the largest public health service in Victoria: Yes

Which state government uses AI to predict hospital demand: Queensland Government

How much has the federal government committed to strengthen public hospitals: AU$7.9 billion

How much could smart health services save Australia annually: Over AU$5 billion per year

How long does traditional drug development typically take: 10 to 15 years

How much does traditional drug development typically cost: Over AU$1 billion

Can AI compress drug development timelines: Yes

What is the compressed drug development timeline AI can achieve: 18 to 30 months

By how much can AI cut preclinical drug development costs: 50 to 80 percent

How many AI-discovered drugs were in clinical trials as of 2025: Over 31

What is the global AI drug discovery market expected to reach by 2034: US$16.5 billion

What CSIRO platform uses AI for high-content analysis in drug research: HCA-Vision

Which CSIRO missions support AI drug discovery tools: AI4Missions, Antimicrobial Resistance Mission, Infectious Disease Resilience Mission

What is the primary regulatory body for AI medical devices in Australia: Therapeutic Goods Administration (TGA)

What legislation governs medical devices in Australia: Therapeutic Goods Act 1989

Must AI medical devices be listed on the ARTG: Yes, unless specifically exempt

What does ARTG stand for: Australian Register of Therapeutic Goods

Does the TGA regulate AI tools that diagnose, monitor, or treat health conditions: Yes, as medical devices

Can digital scribes that suggest diagnoses be regulated as medical devices: Yes, under TGA rules

Does TGA jurisdiction apply to international AI health platforms operating in Australia: Yes

Did the TGA consult on AI regulation in late 2024: Yes

Did the TGA's 2024 consultation find the current regulatory framework adequate for AI: Largely yes

Are further tweaks to TGA definitions expected: Yes

When did the Government approve further work on TGA AI findings: January 2025

Is further TGA guidance on adaptive and generative AI expected: Yes

Must AI medical device training data be generalisable to Australian populations: Yes

Must manufacturers provide evidence of algorithm and model design to TGA: Yes

Must TGA evidence submissions describe training and testing phases: Yes

Does TGA evidence need to address AI-specific risks like overfitting and bias: Yes

Does TGA evidence need to address data drift: Yes

Does TGA compliance require post-market monitoring: Yes

Does AHPRA issue guidance on AI use in clinical practice: Yes

Must clinicians exercise independent judgement when using AI medical devices: Yes, per AHPRA obligations

Is TGA compliance alone sufficient for clinical AI deployment: No, AHPRA obligations also apply

What percentage of AI healthcare applications involve diagnosis: 42%

What percentage of AI healthcare applications involve treatment planning: 46%

What percentage of small health businesses are using AI: 51%

What percentage of SMEs have no plans to adopt AI due to privacy concerns: 32%

Was the healthcare sector among the top data breach sectors in Australia in 2022: Yes

Which body reported healthcare as a top data breach sector in 2022: Office of the Australian Information Commissioner (OAIC)

Are most AI clinical decision support algorithms used in real-world clinical practice: No, few are used in practice

What is identified as the defining challenge for healthcare AI deployment: Translating models into real-world clinical practice

Is technical infrastructure for AI-CDSS deployment well explored: No, minimally explored

Which university centre published the 2025 JAMIA study on AI-CDSS implementation: Centre for Digital Transformation of Health, University of Melbourne

Does adaptive AI that updates post-deployment require a new Device Change Request: Yes, for significant changes

Does the Privacy Act 1988 apply to offshore AI data processing for Australian patients: Yes

What are the Australian Privacy Principles relevant to: Cross-border data flows and patient data handling

Which CSIRO program is developing AI tools to accelerate drug discovery: AI4Missions initiative

What compound annual growth rate is projected for Australia's AI healthcare market to 2030: 46.72%

What was Australia's AI healthcare market size in 2022: Approximately AUD 80 million

Who leads the joint University of Melbourne and Royal Melbourne Hospital digital innovation initiative: Professor Peter Steel

Does the CSIRO HCA-Vision platform operate internationally: Yes, used in Australia and overseas

What is the key gap identified in AI-CDSS research: Gap between model development and real-world deployment